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LIST OF ABBREVIATIONS USED 
 
SGA  : Small for Gestational Age. 
FGR   : Fetal Growth Restriction. 
HTD   : Hypertensive Disorders of Pregnancy.  
HZ   : Hertz. 
KHZ  : Kilohertz. 
MHZ  : Megahertz. 
USG  : Ultrasound. 
SD  : Standard Deviation. 
AC   : Abdominal Circumference. 
HC  : Head Circumference. 
TCD  : Transcerebellar Diameter. 
FL  : Femur  Length. 
EFW  : Estimated Fetal Weight. 
PI  : Ponderal index. 
BP  : Blood Pressure. 
HT  : Hypertension. 
AFI  : Amniotic Fluid Index. 
BPP  : Bio-Physical Profile. 
NST  : Non-Stress Test. 
LBW  : Low Birth Weight. 
 
NHBPEP : National  High Blood Pressure Education Programme. 
PGE2  : Prostaglandin E2. 
IUD   : Intrauterine Death. 
WKS  : Weeks. 
SLE  : Systemic  Lupus Erythematous. 
ACOG : American College of  Obstetrics and Gynaecology. 
NICU  : Neonatal intensive care unit. 
Sensi  : Sensitivity. 
Speci  : Specificity. 
PPV  : Positive Predictive Value of the test. 
NPV  : Negative Predictive Value of the test. 
LR Positive test : Likelihood Ratio for Positive Test. 
LR (-) test  : Likelihood  Ratio for Negative Test. 
H/O   : History of 
FP   : Percentage of False Positive. 
FN   : Percentage of False Negative. 
TP   : True Positive.  
TN   : True Negative. 
PI   : Pulsatility Index. 
RI   : Resistance Index. 
PIH   : Pregnancy induced hypertension. 
IUGR   : Intrauterine Uterine Growth Restriction. 
 
 
 
DV   : Ductus Venosus 
SBP   : Systolic Blood Pressure. 
DBP   : Diastolic Blood Pressure. 
 
 INTRODUCTION 
 
Pregnancy and child birth is a unique experience in women’s life. 
Every woman has her own expectation and emotions for delivering a 
healthy child.  
 
The primary aim of antenatal care is to achieve at the end of 
pregnancy, a healthy mother and a healthy baby. Recently there have 
been many modern investigative and treatment modalities to provide a 
good health care. Despite advances  in antenatal  care , hypertensive 
disorder in pregnancy  contributes  to increased  maternal morbidity and 
mortality and thereby accounts  for increased  perinatal  morbidity  and  
mortality. 
 
Major cause of maternal mortality  according to 2001-2003 SRS 
survey are Hemorrhage (38%),sepsis(11%),hypertension(5%),obstructed  
labour(5%),abortion(8%), and  other  conditions(34%). 
 
Main pathophysiology in preeclampsia and fetal growth restriction 
is impaired uteroplacental and fetoplacental circulation respectively. 
 
Pathophysiology in preeclampsia is absence of secondary wave of 
trophoblastic invasion into spiral arterioles at deciduo - myometrial 
invasion. So the muscular tissues in the tunica media layer is not 
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 destroyed leading to persistence of high resistant vessels, leading to 
decreased uteroplacental circulation. 
 
Colour Doppler ultrasound of uterine artery at 20-22 weeks of 
gestation showing persistent diastolic notch helps in predicting pregnancy 
induced hypertension and intrauterine growth restriction. 
 
Normally the early diastolic notch persists till 22 weeks after which 
there will be disappearance of diastolic notch. Persistence of diastolic 
notch beyond 22 weeks indicates defective placentation. 
 
The study is conducted  to predict  pregnancy induced hypertension 
and intrauterine growth restriction  by using uterine  artery Doppler  and  
thereby  to follow  up  the risk patients and to reduce both maternal and 
perinatal morbidity  and mortality.   
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AIM   OF THE STUDY 
 
To  find out  the sensitivity of uterine  artery doppler  in prediction 
of  pregnancy induced  hypertension  and intrauterine   growth  restriction  
at 20-22 weeks  of  gestation thereby to follow  up the at risk patients and 
to improve  perinatal outcome. 
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 REVIEW OF LITERATURE 
 
Fetal growth restriction 
Fetus with estimated weight below the 10th percentile for a given 
gestational age, due to a pathologic process that inhibits intrinsic growth 
potential.(1,2) is called  fetal growth restriction.(ACOG-2000)(3). 
 
Small for gestational age and fetal growth restriction are frequently 
used to describe the small fetus. About 50%-70% of small-for-gestation 
fetuses are constitutionally small but healthy.20% of SGA fetuses are 
classified as having true FGR, associated with chromosomal anomalies, 
chronic infections. In fetal growth restriction there is a pathological 
restriction of growth both in cell size and number. 
 
INCIDENCE 
10% in developing countries(4). 
5-7% in developed countries. 
 
RISK FACTORS FOR FGR 
∗ Extremes of reproductive age (younger than 16yrs and older than 
35 yrs). 
∗ Poor maternal weight gain. 
∗ Poor pre-pregnancy weight. 
∗ Severe malnutrition. 
4 
 
 ∗ low socio-economic status 
∗ Maternal medical conditions 
• hypertension 
• Renal disease 
• Diabetes (with microvascular disease) 
• Cyanotic heart disease 
• Antiphospholipid syndrome 
• collagen vascular disease 
• Hemoglobinopathies 
∗ Chromosomal anomalies 
∗ Structural anomalies 
∗ primary placental disease 
∗ Infections 
∗ exposure to teratogens. 
 
ETIOLOGICAL FACTORS IN FGR 
∗ Placental causes 80% 
∗ Maternal disease 5% 
∗ Fetal chromosomal anomalies 5% 
∗ Fetal infections 5% 
∗ Multifactorial fetal abnormalities 2-4% 
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 TYPES OF FGR 
TYPE 1 or Symmetric FGR- Intrinsic FGR 
 Fetuses that are symmetrically small and have normal H/A and F/A 
ratios. Defect is in the fetus. 
 Causes-chromosomal abnormalies,viral infections. 
 Prognosis-poor. 
 
TYPE 2 or asymmetric FGR-extrinsic FGR 
 Fetuses are initially symmetric but become asymmetric later in 
pregnancy. 
 Causes-uteroplacental disease, maternal disease. 
 Prognosis-good. 
 
ETIOPATHOGENESIS OF FGR 
Placental causes 
Most common cause 
1. Incomplete trophoblastic invasion of the spiral arteries in the 
placental bed. 
2. Accelerated atherosclerosis of spiral arteries. 
3. Increased no. of synctial knots, obliteration of arteries in tertiary 
stem villi, stromal fibrosis. 
4. Placental infarction and thrombosis due to factor V leiden mutation 
and antiphospholipid syndrome. 
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 5. Chronic villitis,hemorrhagic endovasculitis,placental mosaicism. 
Lymphocytic and histiocytic infiltration of villi are markers of 
chronic villitis 5. 
 
FETAL CAUSES 
 Chromosomal abnormalities especially trisomy 18. 
 Viral infections like congenital rubella, cytomegalovirus, varicella, 
HIV, Herpes simplex virus. 
 Osteogenesis imperfecta. 
 Multiple pregnancy, heart diseases. 
 
MATERNAL CAUSES 
 Chronic hypertension 
 Chronic renal disease 
 Diabetes 
 Preeclampsia 
 Grade 3,4 heart disease 
 Smoking, alcohol, tobacco chewing. 
 SLE 
 Fever, sickle cell anemia, malnutrition. 
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 UTERINE CAUSES 
 Bicornuate uterus, didelphis uterus. 
 Fibroid uterus. 
 
FETAL AND NEONATAL PROBLEMS WITH FGR 
 
Complications 
∗ Antepartum complications 
∗ Intrapartum complications 
∗ Neonatal complications 
 
Antepartum complications 
∗ Fetal hypoxia,acidosis 
∗ Still birth 
∗ oligohydramnios.  
 
Intrapartum complications 
∗ hypoxia,acidosis. 
 
Neonatal complications 
∗ Respiratory disress syndrome 
∗ Meconium aspiration syndrome 
∗ Persistent fetal circulation 
∗ Intraventricular bleeding, more in preterm FGR(6) 
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 ∗ Hypoglycemia 
∗ Neonatal encephalopathy 
∗ Hyperviscosity syndrome 
∗ Hypocalcemia 
∗ Hypothermia 
 
Long term prognosis 
∗ Cerebral palsy 
∗ Adult disease like diabetes, hypertension,coronary heart disease. 
 
In newborns affected by FGR there is increased risk of HT,DM,ischemic 
heart disease.(7,8,9) 
 
ANTENATAL DIAGNOSIS OF FGR 
 Recognition and confirmation of FGR 
 Identification or exclusion of pathological conditions 
 
Assessment of risk factors 
 Presence of risk factors like preeclampsia, maternal hypertension, 
lupus erythematosus, IDDM with vascular disease, cyanotic heart 
disease. 
 Previous birth of a FGR infant. 
 Medications like anticonvulsants, warfarin, antineoplastic agents. 
 Low PAPP-A in first trimester screening ,elavated levels of HCG, 
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 inhibin, AFP in triple or quadruple screening is associated with a 
five-fold increase in FGR when the fetus is unaffected by trisomy 
or neural tube defects.(Gagnon et al,2008) (10) 
 Notching or increased Pulsatility index in 1st and 2nd trimester is 
associated with increased risk of FGR. 
 
PHYSICAL EXAMINATION 
Discordance between gestational age and symhysio - fundal 
height>4 cm. Symphysio-fundal height measurements are helpful, but not 
sensitive in detecting FGR(Harding,1995) (11) 
 
These indicators, combined with maternal history and risk factors 
serve to indicate additional ultrasound evaluation. 
 
USG PARAMETERS 
 Biparietal diameter. 
 Head circumference. 
 Abdominal circumference. 
 Femur length. 
 Estimated fetal weight. 
 
Women with negative uterine doppler screening are at low risk of 
FGR (Negative predictive value of 97% - 99%) (1), and can be followed as 
normal pregnancies. 
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 UTERINE ARTERY DOPPLER SCREENING 
Presence of bilateral diastolic notch in uterine arteries is the 
predictor of FGR. 
 
DIAGNOSIS  
It depends on 
 Correct estimation of gestational age, preferably in the 1st trimester. 
 Gestational age based on LMP using Naegeles rule is uncertain in 
20%-40% of cases. 
 Gestational age is best established in 1st trimester using CRL 
measurement. Predictive error of EDD based n CRL is 7 days. 
 
USG PARAMETERS 
HC/AC RATIO 
 It compares the most preserved organ (brain) with the most 
affected organ (liver). 
 HC/AC is normal in symmetric FGR. 
 HC/AC is increased in asymmetric FGR,>95%percentile for 
gestational age. 
 Normally HC/AC ratio is >1 upto 36 weeks. After 36 weeks the 
value of HC/AC ratio is <1 (12). 
 Head circumference is measured at the level of thalami. Abdominal 
circumference is measured at the level of bifurcation of hepatic 
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 vein in the center of fetal liver. 
 An abdominal circumference within normal range reliably excludes 
FGR with false negative rate of <10%. 
 AC and estimated fetal weight <10%centile are the most accurate 
diagnostic measurements to predict FGR. 
 
GESTATIONAL AGE IS UNCERTAIN 
Following parameters are used 
 
 Trancerebellar Diameter / Abdominal Circumference Ratio. 
 The distance between the outer borders of the cerebellum is not 
affected in FGR. 
 The normal TCD/AC ratio is 0.137 + 0.01. 
 TCD in cm = gestational age in weeks upto 32 weeks. 
 
FEMUR/ABDOMINAL CIRCUMFERENCE RATIO 
 Femur length is least affected by FGR and by position or 
moulding. 
 F/A ratio is constant at 22 + 2 after 20 weeks. 
 Increased F/A ratio suggests FGR. 
 
PONDERAL INDEX  (PI) 
 PI remains constant after 2nd trimester (13) 
 PI=EFW/(FL)3X100 
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  Normal value is 8.325 + 2.5 
 If PI is <= 7 it is FGR. 
 PI has negative predictive value of 96.4% 
 
GROWTH CHARTS 
∗ Serial ultrasounds at intervals of two to four weeks for evaluation 
of fetal growth with the use of standardised growth curves 
demonstrate growth velocity. 
∗ Decreased growth velocity is an important indicator of FGR. 
∗ Suspect FGR when AC deviates 10% or more from the individual 
projected growth curve. 
 
AMNIOTIC FLUID VOLUME(AFI) 
1. AFI is important both in diagnosis and prognosis for FGR. 
2. Oligohydramnios is highly suggestive of FGR and indicates 
increased risk of Perinatal mortality. 
3. About 77%-83% of pregnancies with FGR will have 
oligohydramnios ultrasonographically. (Philipson et al1983) (14,15). 
4. AFI is normal even in a fetus with FGR. Therefore absence of 
oligohydroamnios does not rule out the diagnosis of FGR. As a 
rule of thumb, pregnancies with the most severe oligohydramnios 
have the highest perinatal mortality rate, highest incidence of 
congenital anomalies and FGR. 
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 MANAGEMENT (15) 
1. Confirm the diagnosis 
2. Exclude fetal anomalies 
3. Treat the underlying cause 
4. Fetal surveillance 
5. Treatment for FGR  
                                                                                                                                                  
EXCLUDE FETAL ANOMALIES AND UNDERLYING CAUSE 
Chromosomal defects and multifactorial congenital malformations 
20 to 30% of fetus with an AC and EFW less than fifth percentile have 
chromosomal defects and multifactorial congenital malformations. The 
percentage is much higher if FGR is diagnosed before 26 weeks of 
gestation and associated with polyhydramnios.(11) 
 
Structural abnormalities 
A detailed anatomical ultrasound survey must be done to rule out 
structural abnormalities. It may also be appropriate to offer karyotyping 
in early onset FGR (Snijders,1993) (16). 
 
Fetal infections 
Infections that develop early in pregnancy have the greatest effect on 
subsequent growth, but account for less than 5% of FGR. 
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 • Multiple gestations are associated with both preterm delivery and 
FGR. 
• Maternal vascular disease with its associated decrease in 
uteroplacental perfusion accounts for 20% of FGR. It is the most 
common cause for FGR in non anamalous fetus.(17). 
 
Fetal surveillance 
1. The goal of antepartum surveillance in FGR is to safely continue 
the pregnancy and intervene when the intrauterine environment is 
hostile to the fetus. 
2. Antepartum surveillance with doppler of the umbilical artery and 
MCA is initiated when FGR is suspected and the fetus is viable. 
3. Antepartum surveillance aims to  
a. Identify small, yet healthy, fetuses and support these 
pregnancies appropriately. 
b.  Identify FGR fetus at risk and intervene appropriately. 
 
UMBILICAL ARTERY DOPPLER 
• Umbilical artery doppler helps to differentiate a normal SGA fetus 
from the FGR fetus.  
• Indices of umbilical artery doppler waveforms such as resistance 
index. 
• Systolic/ diastolic ratio and pulsatility index are useful for 
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 predicting perinatal outcome. 
• Umbilical artery doppler waveform is considered abnormal if 
diastolic flow is reduced, absent or reversed after 20 weeks 
gestation.  
• Absent or reverse flow in umbilical artery is associated with 60 to 
70% obliteration of placental arteries and high perinatal 
mortality.(Kingdom 1997)(18)    
 
Abnormal umbilical artery indices are strong predictors of poor perinatal 
outcomes like  
 Low APGAR score 
 Late deceleration 
 Severe variable decelerations 
 Absent variability 
 Low fetal scalp pH  
 Presence of thick meconium 
 Admission to NICU 
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 Clinical significance of umbilical artery doppler in FGR 
∗ When an anomaly scan and umbilical artery doppler are normal 
and the liquor is adequate, the small fetus is likely to be a normal 
small fetus. 
∗ Outpatient management with frequent monitoring of such fetus is 
safe. 
∗ Abnormal umbilical artery doppler is an indication for enhanced 
fetal surveillance or delivery. 
  
MIDDLE CEREBRAL ARTERY DOPPLER 
 Umbilical artery doppler waveforms in isolation are unsuitable as a 
test for fetal well being. They do not reflect fetal responses or 
placental insufficiency accurately to predict perinatal outcome. 
 Fetal hypoxemia causes cerebral vasodilation - “brain sparing” 
effect. Redistribution of cardiac output occurs with increased blood 
flow to the brain, heart, adrenals and reduced flow to kidneys and 
muscles. 
 Reduced Pulsatility index in the MCA doppler suggests 
redistribution of blood to the brain. 
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 DOPPLER OF THE VENOUS SYSTEM 
 Doppler studies of the venous circulation are indicated when FGR 
fetus shows brain redistribution. 
 Umbilical vein can be screened. 
 Ductus venosus (DV) is identified as the aliasing point at the top of 
the intrahepatic vein. Progressively deep a-wave in the ductus 
venosus is an indicative of right heart strain in the fetus and 
correlate with fetal acidosis at delivery. 
 
Typical progression of multi-vessel doppler studies with progressive 
placental dysfunction in FGR. 
 
 Elevated umbilical artery S/D ratio. 
 MCA PI<5th percentile(brain sparing). 
 Umbilical artery-absent diastolic flow. 
 Umbilical artery-reversed diastolic flow. 
 Ductous venosus-elevated PI. 
 Ductous venosus-reversed a-wave. 
 Umbiical vein double pulsations. 
 Umbilical vein triple pulsations with reversed a-wave. 
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 INTEGRATED FETAL TESTING  
Baschat (2003) (19) has suggested multiple testing to monitor FGR 
 Periodic fetal biometry 
 AFI 
 Multi vessel arterial and venous doppler. 
 Biophysical profile (BPP). 
 Fetal heart rate monitoring (CTG). 
 Fetal movement counting. 
 
TREATMENT 
No effective therapies for FGR available. 
 
BED REST 
The idea behind this is that blood flow to placenta increases .But 
Laurin and Person conducted randomised control trial and said that there 
is no role in bed rest.(20) 
 
HYPEROXYGENATION 
Nicolaides et al (21) and Battagia (22) et al found decrease in fetal 
mortality when mother is exposed to oxygen. 
 
ASPIRIN 
Aspirin inhibits thromboxaneA2 and changes thromboxane to 
prostacycline. It causes vasodilation in uteroplacental circulation and 
thereby decreases the incidence of FGR and preeclampsia (23)(24). 
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 OPTIMAL TIME OF DELIVERY 
∗ FGR fetus is chronically hypoxemic. Continued intrauterine 
hypoxia leads to metabolic deterioration. 
∗ Fetus should be delivered if the risk of fetal death increases. 
ACOG (2000)(3). 
∗ A fine balance needs to be made between prematurity and 
intrauterine hypoxia (GRIT STUDY-2003)(25). 
∗ Growth restriction intervention trial concluded that if the fetus is at 
<31 weeks gestation, it is best to delay delivery(26). 
 
DETERMINANTS OF TIMING OF DELIVERY oF FGR FETUS 
 Etiology of FGR 
 Biophysical profile 
 Non stress test 
 Fetal movement 
 AFI 
 Doppler velocimetry 
 Interval growth 
 Gestational age 
 Maternal co-morbidities 
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 MANAGEMENT BASED ON GESTATIONAL AGE 
BEFORE 26 WEEKS 
 Outcome is extremely poor in view of extreme prematurity and 
FGR. 
 Delivery is indicated only for maternal indications like severe 
preeclampsia 
 Survival is<50% and the long term handicap is around 30-50% 
 Option of non intervention and probable IUD should be given in 
the absence of maternal disease and risk. 
 
26-28 WEEKS 
 Administer steriods to enhance lung maturity. 
 Monitor fetus for signs of worsening hypoxia 
 Decision to deliver depends on the intensive care for these babies. 
 
28-31 WEEKS 
 Risk of perinatal mortality is high due to prematurity, Doppler 
studies of the ductus venosus may be used to assist in decision 
making. 
 Normal flow in ductus venosus may allow extension of pregnancy 
to 32-34 weeks if other tests of wellbeing remain reassuring. 
 Administer two doses of steroids before delivery. 
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 32-36 WEEKS 
 Risk of respiratory distress syndrome is reduced. 
 A primary factor that should be considered after 34 weeks of 
gestation is the risk of fetal death, Late onset FGR contributes to 
>50% of unanticipated stillbirths at term. 
 
MODERATE FGR 
 Consider induction of labour if the fetus is > or =36 weeks of 
gestation age. 
 Delivery can be delayed until after 37 weeks in the presence of 
normal diastolic flow in the umbilical artery and other surveillance 
findings being normal. 
 
SIGNIFICANT GROWTH RESTRICTION 
Consider delivery if imminent signs of fetal compromise as 
 Non-reactive NST 
 Poor baseline variability 
 Persistent variable or late decelerations are present. 
 
>36 WEEKS 
 Consider delivery in FGR with oligohydramnios >36 weeks 
 Induction of labour with careful fetal monitoring is important as 
these fetuses will not tolerate acute hypoxia. 
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  DIGITAT (Disproportionate Intrauterine Growth Intervention Trial 
At Term) study showed no difference in perinatal outcomes, if after 
36 weeks” delivery was by induction of labour or by expectant 
management.(Boers,2010)(27) 
 
MODE OF DELIVERY 
Due to increased prevalence of chronic hypoxia and 
oligohydramnios among FGR, the rate of cesarean section will increase. 
 
Indications for cesarean section 
 Severe FGR with EFW <1.5 kg 
 Preterm FGR <32 Weeks 
 Non-reassuring fetal heart rate 
 Metabolic acidosis and 
 Other obstetric indications. 
 
During labour perform continuous intrapartum fetal monitoring to 
detect non - reassuring fetal heart rate indicating progressive hypoxia and 
provide intensive neonatal care. 
 
RECURRENT RISK FOR FGR 
Risk of FGR in 2nd pregnancy is 29% and the risk in third 
pregnancy rises to 44% after two FGR (Bakketeig and Hoffman, 1983)(28). 
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 HYPERTENSIVE DISORDERS OF PREGNANCY 
Hypertensive disorders  in pregnancy is the major cause of 
maternal death all over the world. A diagnosis of hypertension in 
pregnancy increases a woman’s risk of developing chronic hypertension 
and cardiovascular problems. It increases the risk to the baby in the form 
of still birth, preterm birth and FGR.  
 
DEFINITIONS 
According to National High Blood Pressure Working group 
(NHEPEP) and ACOG, hypertension in pregnancy is defined as systolic 
blood pressure >140mm of Hg and diastolic blood pressure>90mm of Hg 
in a previously normotensive woman after 20 weeks of gestation on two 
occasions 4-6 hours apart. 
 
Diastolic blood pressure is the disappearance of sounds (Kortkoff 
Phase V). Blood pressure should be measured in sitting or in left lateral 
position with the arm at the level of heart. An appropriately sized cuff 
(length 1.5 times the circumference of the arm) should be used. If BP is 
high in one arm, the arm with the higher value should be used for all BP 
measurements. 
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 CLASSIFICATION OF HYPERTENSIVE DISORDERS 
 GESTATIONAL HYPERTENSION : It refers to elevated blood 
pressure, first detected at 20 weeks of gestation, in the absence of 
proteinuria or other features of preeclampsia. 
 
 PREECLAMPSIA : It refers to the syndrome of new onset of 
hypertension and proteinuria, often after 20 weeks of gestation, in a 
previously normotensive woman.Edema and weight gain excluded 
from the criteria. 
 
 ECLAMPSIA : convulsions occurring in a patient with 
preeclampsia.It can occur with hypertension or proteinuria. 
 
 CHRONIC HYPERTENSION : It is defined as systolic 
pressure>140/90mm of Hg and >90 mm of Hg that antedates 
pregnancy, or it is before 20 weeks of pregnancy or persists beyond 
12 weeks post partum. 
 
 PREECLAMPSIA - ECLAMPSIA SUPERIMPOSED UPON 
CHRONIC HYPERTENSION; This is diagnosed when a women 
with chronic hypertension develops increasing hypertension with 
new onset proteinuria or features of preeclampsia (elevated liver 
enzymes, low platelet count). 
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 • Mild gestational hypertension is SBP 140-159mm of Hg and DBP 
90-109 mm of Hg. 
• Severe GHT is SBP >= 160 mm of Hg and / or DBP >= 110 mm of 
Hg. 
• White coat hypertension is DBP >= 90 mm of Hg in office, but 
<135/85 mm of Hg at home (Pickering et al). 
 
 HELLP syndrome: Includes  
o Hemolysis 
o Elevated liver enzymes 
o AST > 70 U/L 
o LDH > 600 U/L 
o Thrombocytopenia (<1 lakh mm3) 
 
PROTEINURIA  
∗ 15- 25% of gestational hypertension progress to preeclampsia. 
Urine dipstick testing is performed on a fresh, clean voided, 
specimen before pelvic examination. 
 
RESULTS 
 Negative 
 Trace 
 1+ =  between 30 and 100 mg/dl 
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  2+   =between 100 and 300 mg/dl 
 3+    = between300 and 1000 mg/dl 
 4+   =   >1000 mg/dl 
 Proteinuria > 2+ is significant 
 Proteinuria > 1+ should be followed by mid-stream urine culture to 
rule out infection and to check for significant proteinuria. 
 24-hr urine collection is the gold standard to quantify protein 
>=300mg/d in 24 hr urine collection is significant proteinuria. 
Now-a-days 24-hour test is replaced by spot urine protein 
creatinine ratio.(Durnwald and MERCER,) 
 
INCIDENCE 
 6-15%Nullipara 
 2-4% multipara (29,30) 
 
RISK FACTORS 
 Young age. 
 Nullipara 
 Race 
 Environmental factors 
 Maternal >35 yrs 
 Multiple pregnancy 
 Molar pregnancy 
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  Smoking decreases risk of Preeclampsia(1) 
 
HIGH RISK FACTORS 
 Previous preeclampsia 
 Antiphospholipid antibody syndrome. 
 Preexisting DM, HT. 
 Women with SLE. 
 Chronic renal disease. 
 
MODERATE RISK FACTOR 
 Multiple pregnancy. 
 Primi 
 Maternal age >40 yrs. 
 BMI>35 kg/m2 
 Family history of preeclampsia. 
 Interpregnancy interval >10 yrs. 
 
ETIOPATHOGENESIS OF PREECLAMPSIA 
 Increased risk of preeclampsia in women exposed to chorionic villi 
for first time. 
 Hyperplacentosis (abundance of chorionic villi-twins, mole) 
 Genetic predisposition 
 Abnormal trophoblast invasion 
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  Immunological maladaptation to inflammatory changes.(1) 
 Calcium and magnesium deficiency(35) 
 
NORMAL PLACENTATION 
Initially 4 weeks after implantation of fertilized ovum low resistant 
vessels are seen in the future placenta (31) 
 
At 10-12 weeks, first wave of trophoblast invasion occur upto 
decidual segments. 
 
At 16 weeks, second wave of extravillous trophoblasts invasion of 
spiral arterioles occurs upto inner third of myometrium.(32) ,thereby the 
musculoelastic and neural tissue element in the spiral arterioles are 
destroyed converting high resistant vessel into low resistant high flow 
vessels. 
 
In preeclampsia, there is failure in second wave of trobhoplastic 
invasion. So musculoelastic media of spiral arterioles remain intact and 
respond to vaspressor agents (32) 
 
Placental bed biopsies in preeclampsia-necrotising lesion with 
foam cells in spiral arteries (acute atherosis) (33) (34). 
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 CANDIDATE GENES 
Polymorphisms of FAS, hypoxia-inducible factor-1 alpha 
protein,IL-1 beta,lymphotoxin-alpha,TGF-beta,TNF could be the cause of 
preeclampsia.(35) 
 
ENDOTHELIAL ACTIVATION 
 Activated lymphocytes in maternal placental debris is responsible 
for endothelial cell activation. 
 Cytokines like IL, TNF alpha are associated with preeclampsia. 
 Other factors like  
 
 Intense vasospasm 
 Increased  pressor responses to angiotensin 2 
 Prostacycline : thromboxane ratio decreases 
 Decreased nitric oxide 
 Increased endothelin (35) 
 
ANGIOGENIC  AND ANTIANGIOGENIC PROTEINS 
 Soluble FMS- like tyrosine kinase 1 (sflt-1) is a variant of flt-1 
receptor for placental growth factor and vascular endothelial 
growth factor. 
 Increased maternal sflt-1 inactivate  and decrease VEGF and PIGF 
leading to endothelial dysfunction.(35) 
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  Soluble endoglin (sEng) is a placenta derived molecule that block 
endoglin, thereby decrease NO dependent vasodilatation (35). 
 
PATHOPHYSIOLOGY 
 Endothelial cell damage leads to fluid leakage into the third space. 
This leads to decreased intravascular volume and 
hemoconcentration. 
 Liver edema and hepatocellular damage increases LDH and serum 
transaminase levels. Stretching of Glissons capsule leads to 
epigastric pain, and sometimes hepatic hemorrhage. 
 Vasospasm and glomerular endotheliosis lead to decreased renal 
blood flow and GFR.Glomerular demage leads to proteinuria. 
Persistent oliguria leads to acute tubular necrosis and ARF. 
 Cerebral hypoxia results in headache, scotoma, blurred vision and 
hyperreflexia. Cerebral hemorrhage and stroke occurs in severe 
cases. 
 Endothelial damage leads to coagulation cascade activation and 
DIC. 
 Thrombocytopenia occurs due to microangiopathy. 
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 Pathophysiology and Complications of Pre-eclampsia 
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 INVESTIGATIONS 
 Urine analysis-proteinuria 
 Hb-raised (hemoconcentration, except in hemolysis) 
 Platelet-low. 
 Peripheral smear-schistiocytes. 
 INR and APTT-higher in DIC. 
 Serum creatinine-higher 
 ALT,AST,LDH-higher 
 Albumin-lower 
 Bilirubin –higher. 
 FUNDUS examination. 
 
MANAGEMENT OF HYPERTENSIVE DISORDERS IN 
PREGNANCY 
Pre-conceptional advice 
1. Women with preexisting hypertension should have an of the 
medication they currently take. 
2. Angiotension converting enzyme inhibitors, atenalol, statins, 
thiazides have an adverse effect on fetus, so discontinue the drug. 
3. According to NICE guidelines, women with atleast one high and 
two moderate risk factors of preeclampsia should be given 75mg of 
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 aspirin daily, from 12 weeks of pregnancy till the delivery of the 
baby.(36) 
4. Investigations like serum potassium, creatinine and urine analysis 
should be done prior to woman with history of chronic 
hypertension. 
 
TREATMENT OF HYPERTENSION 
 Aim to maintain BP <150/100 mm of Hg. Overzealous treatment of 
hypertension should be avoided. In patients with DM, systolic BP 
should be maintained between 130 mm ofHg-139mm of Hg. 
Diastolic Bp between 80-89 mm of Hg. 
 SOGC guidelines (2008)(37) suggest that 
∗ Women with mild-moderate HT and without co-morbid 
conditions should have antihypertensive to lower DBP to 80-
105 mm of Hg. 
∗ Hypertensive women with co-morbid conditions like DM, 
chronic HT and renal disease should have systolic BP 130-
139 mm of Hg and DBP of 80-89mm of Hg. 
∗ In patients with severe HT maintain  SBP of 140-150 mm of 
Hg and DBP of 90-100 mm of Hg. 
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 DRUGS 
∗ Labetalol. 
∗ Nifedepine. 
∗ Alpha methyl dopa 
NICE recommends Labetalol as first line medication. But avoid 
labetalol in asthmatic patients. 
 
 LABETALOL 100-400 mg bd-tds (maximum of 1200mg/d) side 
effects - Postural hypotension, tiredness. 
 METHYLDOPA 250-500 mg tds-qid  (maximum of 2g/d) side 
effects-headache, dizziness, hypotension, headache. 
 NIFEDEPINE- 10-20mg bd S.E- hypotension, headache and nasal 
congestion. 
 
CORTICOSTEROIDS  
 Women with preeclampsia before 34 weeks should have steroids 
for fetal lung maturity. 
 12mg of betamethasone given IM 24 hrs apart, 2 doses.(RCOG-
2010).(38) 
 
PREDICTION (35) 
 Placental perfusion – roll over, isometric hand grip, midtrimester 
mean arterial pressure and uterine artery doppler. 
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  Fetal-placental unit - endocrine dysfunction - HCG, Alpha 
fetoprotein, estriol, PAPPA, inhibinA, activinA, placental  protein-
13, corticotropin releasing hormone. 
 RENAL DYSFUNCTION- serum uric acid, microalbuminuria, 
urinary calcium or Kallikrein, microtranferrinuria, N-acetyl beta 
glucosaminidase. 
 Endothelial dysfunction-platelet count, fibronectin, endothelial 
adhesion molecule, prostaglandin, CRP, PAI, leptin, PIGF, sflt-l. 
 Miscellaneous-Antithrombin-lll,Atrial natriuretic peptide, beta2-
microglobulin,serum proteonomic markers. 
 
TIMING OF DELIVERY (according to ACOG ) 
 38-39 weeks of gestation for women not requiring medication. 
 37-39 weeks for women with controlled hypertension with 
medication. 
 36-37 weeks with severe hypertension. 
 HYPITAT (Hypertension and Preeclampsia Intervention Trial At 
Term (Koopmans et al, 2009)(39) shows that the outcome of 
pregnancy with gestational HT induced at >37 wks was better  
compared to expectant management. 
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 INTRAPARTUM CARE 
 Vaginal delivery should be considered except for obstetric 
indications. 
 Steroids should be given when gestational age <34 weeks. 
 In case of poor Bishops score, induction should be done with 
prostaglandins. 
 In case of FGR and oligohydramnios,intrapartum monitoring  
should be done. 
 During labour, hourly BP monitoring should be done.Maintain 
BP<160/110 mm of Hg. 
 During labour, continuous fetal monitoring should be done. 
 If BP is controlled, second stage of labour need not be cut short 
routinely. 
 Avoid ergometrine during third stage of labour.Active management 
of third stage of labour should be followed. 
 
MANAGEMENT OF SEVERE PREECLAMPSIA 
Clinical features of severe preeclampsia includes : 
∗ Severe headache 
∗ Vomiting 
∗ Epigastric pain 
∗ Visual disturbances 
39 
 
 ∗ Papilledema 
∗ Oliguria 
∗ Thrombocytopenia 
∗ Elevated liver enzymes. 
∗ HELLP syndrome. 
 
CHOICE OF DRUGS 
Labetalol is the first line of drug. It can be given both orally and 
intravenously. Due to beta receptor blocking activity, it is better to avoid 
in asthmatic. Labetalol causes neonatal hypoglycemia and bradycardia. 
 
OTHER DRUGS IN USE ARE  
 Nifedepine 
 Hydralazine 
 Avoid sublingual nifedepine to reduce BP in patient with volume 
depletion,since it will cause precipitous fall in BP.(NICE,2010). 
 Antidote for Mgso4 toxicity is 10 g of  10%  calcium gluconate 
given  IV. 
 
• Labetalol 20mg IV bolus followed by 40 mg if not effective within 
10 minutes then, 80mg every 10 mins, max dose 220mg. 
• Nifedepine-10mg orally every 30 mins, max of 3 doses. 
• Hydralazine- 5-10mg IV every 15-20 minutes. 
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 DELIVERY OF PATIENT WITH SEVERE PREECLAMPSIA 
 In case of severe preeclampsia, delivery at 34-36 weeks to be 
considered. (Magloire and Funai, (2013)(40) 
 Prophylactic Mgso4 should be given. 
 The only proven treatment of preeclampsia is delivery of the baby. 
 
SEIZURE PREVENTION  
 Magnesium sulphate is the drug of choice for treatment of 
eclampsia, according to MAGPIE  and Collaborative Eclampsia 
Trial).(41) 
 PRITCHARD regimen- 4g iv over 3-5 mins followed by 10 g deep 
im (5g in each buttock). 
 Management during fit : A mouth gag is placed in between teeth to 
prevent tongue bite  and remove the gag after clonic phase. 
 Head to be turned to one side, air passage to be cleared of mucus. 
 Nasal o2 is given until cyanosis disappears. 
 
Pathophysiology of eclampsia 
Loss of cerebral autoregulation leads to either vasodilation or 
intense vasospasm of cerebral arteioles. Cerebral vasoconstriction leads 
to ischemic cytotoxic edema and infarction. When the autoregulation 
fails, vasodilation occurs leading to hyperfusion and vasogenic edema. 
(Sibai BM ,2005). CT shows hemorrhage and infarction in 50% of 
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 eclamptic women. (Brown CEL ,1998).Visual disturbances occur due to 
retinal detachment or occipital lobe lesions and often it is reversible.  
 
HELLP SYNDROME 
 The diagnosis is based on laboratory criteria(Tennassee classification): 
 Microangiopathic hemolytic anemia – schistiocytes and burr 
cells in peripheral smear. 
 Increased serum bilirum > 1.2 mg /100ml 
 Elevated  LDH >600 U /L 
 Platelet count <1 lakh/mm3. 
 Serum AST (SGOT) >70 IU/L 
 Symptoms are vague and lead to delay in diagnosis.Typical symptoms 
are nausea,vomiting,right upper quadrant pain. 
 HELLP may manifest even in the absence of HT. 
 Maternal compications of HELLP occur in the form of 
DIC,pulmonary edema and renal failure. 
 
Differential diagnosis for HELLP syndrome: 
 Acute fatty liver of pregnancy (AFLP) 
 Idiopathic thrombocytopenic purpura. 
 Thrombotic thrombocytopenic purpura. 
 Lupus flare. 
 Hemolytic uremic syndrome. 
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 MANAGEMENT OF HELLP SYNDROME 
 Termination of pregnancy is ideal. 
 For successful outcome,multidisciplinary management is 
important. 
 If platelet count is <20000, give platelet transfusion. 
 Role of steroids and plasmapheresis in HELLP is not clear. 
 
RISK OF RECURRENCE 
 Risk of recurrence of gestational hypertension -15-50%. 
 Women with previous history of preeclampsia, eclampsia, HELLP, 
risk of recurrence in future pregnancy is 25%(if delivery occurs 
before 34 weeks). 
 The risk increases to 55% if previous delivery occurs prior to 28 
weeks). (NICE ,2010) 
                                 
DOPPLER STUDY 
 It is a non invasive technique that uses high frequency sound waves 
to detect blood flow. 
 Study was based on Doppler Effect (42). Doppler effect was 
discovered by Christopher Doppler in 1942. 
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 DOPPLER PRINCIPLES AND VELOCITY MEASUREMENTS 
The ultrasound scanner transmits pulses to detect movement of 
blood. Echoes from stationary tissues are same from pulse to pulse and 
for moving objects light differences exhibits in the time for the signal to 
be returned to receiver. 
 
The differences are measured as phase shift from which doppler 
frequency is measured. As velocity of blood increases, the doppler 
frequency increases. The first application of doppler in obstetrics was 
done by FITGERALD and DRUMM (43). Shigeo Satomura from Japan 
developed first doppler  for diagnostic purposes.(44) 
 
PHYSICAL PRINCIPLES OF DOPPLER USG 
Sound is a form of mechanical energy which travels through both 
liquid and solid media as pressure waves. 
 
The propagation of sound in a medium is the rate of change of 
position of sound wave in unit time. The wavelength of sound comprises 
of one cycle of compression and refraction. It is the distance between pair 
of consecutive peaks or troughs of adjacent pressure waves. 
 
The frequency of sound is the number of cycles in one second. One 
cycle=1 Hertz. Sound frequency ranges from 10HZ-20KHZ is audible. 
Sound with more than 20KHZ frequencies are inaudible to human ear and 
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 are known as ultrasonic waves. In doppler USG frequency range of 2-
10MHZ is employed.2-5MHZ frequency range is used in obstetric 
transducer. 
 
DOPPLER EQUIPMENTS 
Three types 
 
 Continuous wave doppler. 
 Pulsed wave doppler. 
 Colour flow mapping. 
 
CONTINUOUS WAVE DOPPLER 
It uses continuous transmission and reception of ultrasound. 
Continuous wave doppler is unable to determine specific location of 
velocities with the beam and cannot be used to produce color flow 
images. It uses 2 transducers. 
 
PULSED WAVE DOPPLER 
The transmitted beam power of pulsed doppler is higher than that 
of the safety standards for fetus studies recommended by National 
institute for Health. It uses one transducer which emits waves for short 
period and then acts as receiver for reflected waves. 
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 COLOR FLOW DOPPLER 
The color represents direction, magnitude and flow of the 
circulation. The color is based on hue, luminance, and saturation. The 
direction of flow in relation to transducer is in primary colors of blue 
(away from transducer), red (towards the transducer). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Doppler Study 
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 DOPPLER STUDY IN UTEROPLACENTAL INSUFFICIENCY 
Doppler USG is used now-a-days for assessing uteroplacental 
insufficiency thereby preeclampsia and FGR is earlier predicted. It was 
first demonstrated by Campbell in 1983 (45). The feasibility of its fetal 
application was demonstrated by Fitgerald and Drumm(46) 
 
The uterine artery doppler is measured at a point just distal to the 
crossover with the iliac arteries before uterine artery divides into arcuate 
arteries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal Doppler Study in utero placental insufficiency  
 
Normal uterine artery doppler form  
In non pregnant women, there is a steep systolic flow and an early 
diastolic notch showing high vascular resistance (47). At 4 weeks after 
implantation, well defined low resistant vessels are seen in future 
47 
 
 placenta (48). In second trimester, uncoiling of uterine and spiral arteries 
occurs so that low resistance occurs (49.).In later trimester, there is gradual 
removal of notch and increase in diastolic flow and decrease in resistance 
index. Resistance index was used as screening tool, but it has low 
sensitivity. 
 
 Pai et al (50,51,52) found persistent diastolic notch as better screening 
tool than resistant index. 
 
 Bollar et al demonstrated that presence of notch in the artery 
homolateral to placenta was associated with poor prognosis. 
 
 Michael S.Kraner et al (53) mentioned environmental factors like 
stress, low socioeconomic status and overcrowded housing 
increase cortisol levels higher in maternal and fetal circulation and 
that leads to impaired placentation. 
 
INDICES USED IN DOPPLER 
• Arterial system 
• S/D ratio =systolic peak velocity/end diastolic velocity. 
• S-D/S = Resistance index. 
• S-D/Mean frequency shift = pulsatility index. 
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 MATERIALS AND METHODS 
 
This study was conducted to find out the sensitivity of uterine 
artery doppler in predicting pregnancy induced hypertension and 
intrauterine growth restriction at 20-22 weeks of gestation, thereby to 
follow up the at risk patients and to improve perinatal outcome. 
 
The study was conducted at Tirunelveli Medical College hospital 
from june 2013 toAugust 2014 in the department of Obstetrics and 
Gynaecology and in the department of Radiology. 
 
SELECTION OF CASES 
About 200 antenatal mothers were selected and they were separated as  
i. High risk (Group I). 
ii. Low risk (Group II). 
∗ High risk cases include 100 antenatal mothers with previous 
history of hypertension, FGR, IUD at 20-22 weeks of gestation. 
∗ Low risk cases include 100 antenatal mothers (primi / multipara) at 
20-22 weeks with no prior history of hypertension, FGR, IUD. 
 
INCLUSION CRITERIA 
GROUP I 
       Antenatal mother (multipara) with previous history of 
Hypertension, FGR, intrauterine death. 
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 GROUP II 
Antenatal mother (primi/multi) with no history of hypertension, 
FGR, intrauterine death. 
 
EXCLUSION  CRITERIA 
∗ Multiple gestations. 
∗ Antenatal mother with cardiac diseases, DM, SLE, chronic 
hypertension and epilepsy. 
 
METHOD OF STUDY 
All antenatal mothers were registered in Antenatal OP.A detailed 
history elicited and then examination done. After getting consent, doppler 
study done at 20-22 weeks of gestation. The doppler characters studied 
for prediction of pre-eclampsia and FGR was bilateral diastolic notch.  
 
DOPPLER STUDY METHOD 
Antenatal mother is placed in a supine and slightly left lateral 
position to prevent supine hypotension. The frequency of doppler used is 
3.5-5 MHZ. Doppler measurement is done at a point just distal to the 
crossover with the iliac artery before uterine artery divides into arcuate 
arteries. 
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 RESULTS AND ANALYSIS 
Computer statistical analysis was used to analyse the statistics. 
Comparison of data was done using chi-square test. Both univariate and 
multivariate analysis of data was done. 
 
Validity of the tests was evaluated by calculating sensitivity, 
specificity, positive and negative predictive values, likelihood ratio for 
positive and negative test with 95% confidence interval. A likelihood 
ratio of 1 means the test has no predictive value. A likelihood ratio of >10 
or <0.1 should be needed for a +ve and –ve test result respectively. A 
likelihood ratio of 1-5 and 0.2-1 means mild prediction. A likelihood ratio 
of 5-10 and 0.1-0.2 means moderate prediction. A likelihood ratio is 
independent of prevalence and it combines sensitivity and specificity. A 
likelihood ratio has a good predictive value. 
 
In group, I, (High risk) 100 cases and in group II (low risk) 100 
cases were selected and prospectively followed up. 3 cases in group I 
and 2 cases in group II were lost to follow up.  The selected cases had 
uterine artery evaluation between 20-22 weeks gestation and followed 
up for development of hypertensive disorders, fetal growth 
restriction, gestational age at delivery, mode of delivery and perinatal 
outcome. Cases included were mainly belonging to class IV 
socioeconomic status. 
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 1.  AGE DISTRIBUTION OF CASES:- 
Table - I 
 
Age 
No of Cases 
Group – I Group - II 
18 - 20 Yrs 12 25 
(12%) (50%) 
21 - 30 Yrs 71 72 
(71%) (72%) 
31 - 35 Yrs 17 3 
(17%) (3%) 
 
 
In this study, 71 cases (71%) in group I and 72 cases (72%) in 
group II belonged to the age group of 21-30 yrs. 12 cases (12%) in 
group I and 25 cases (25%) in group II belonged to the age group of 18-
20 yrs and the remaining belonged to the age group of 31- 35 years. 
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 2. PARITY DISTRIBUTION CASES : - 
TABLE II 
 
GROUP - I 
 
Parity Count Percentage 
Multi 100 100% 
Primi 0 0% 
Total 100 100% 
 
In Group I, all the 100 cases (100%) were multigravida. 
 
GROUP II 
 
Parity Count % 
Multi 40 40.00 
Primi 60 60.00 
Total 100 100 
 
 
In Group II, 40 cases (40%) were multigravida,60 cases (60%) 
were primigravida. 
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3. NOTCH DISTRIBUTION :- 
TABLE - IV 
GROUP - I 
 
Notch Count % 
Absent 59 60.82 
Bilateral 33 34.02 
Unilateral 5 5.15 
Total 97 100 
 
In Group I, bilateral notch was present in 33 cases (34.02%) 
and unilateral notch was present in 5 cases (5.15%). 
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Table - V 
Group – II 
 
Notch Count % 
Absent 80 81.63 
Bilateral 12 12.24 
Unilateral 6 6.12 
Total 98 100 
 
In Group II, bilateral notch was present in 12 cases (12.24%) 
and unilateral notch was present in 6 cases (6.12%). 
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 4. DISTRIBUTION OF CASES IN RELATION TO PARITY 
TABLE - VI - A 
GROUP - I 
 
 
 
 
 
 
 
 
P = <0.001 
 
In Group I, in cases with persistence of bilateral notch 33 
(100.0%) cases were multi and no cases (0.00%) in primi. In cases 
with persistence of unilateral notch, 5 cases (100.0%) were multi 
and no cases (0.00%) were reported in primi. P value of <0.001 
indicates significant (at 5%) relationship between notch & parity.  
Notch is associated with multigravida. 
 
 
 
Notch Primi Multi Total 
Bilateral 
0 
(0.00%) 
33 
(100.00%) 
33 
Unilateral 
0 
(0.00%) 
5 
(100.00%) 
5 
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 TABLE – VI - B 
GROUP - II 
  
Notch 
Parity 
Total 
Primi Multi 
Bilateral 
8 
(66.7%) 
4 
(33.3%) 
12 
Unilateral 
4 
(66.7%) 
2 
(33.3%) 
6 
 
P value=0.022 
 
In Group II, persistence of bilateral notch were noted in 8 (66.7%) 
of cases in primi and in multi 4 cases (33.3%) were noted. Persistence of 
unilateral notch was noted in 4 cases (66.7%) in primi and 2cases in multi 
(33.3%).  
 
P-value of 0.022 indicates significant relationship between notch 
and parity. Notch is associated with parity. 
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 5. NOTCH AND HTD/FGR:- 
TABLE-VII-A 
GROUP - I 
 
Notch Number 
Normal 
outcome 
HTD FGR 
Bilateral 
33 
(34.0%) 
16 
(48.4%) 
2 
(6.1%) 
15 
(45.4%) 
Unilateral 
5 
(5.1%) 
1 
(20.0%) 
1 
(20.0%) 
3 
(60.0%) 
Total 
38 
(39.2%) 
17 
(44.7%) 
3 
(7.8%) 
18 
(47.3%) 
Absent 
59 
(60.5%) 
51 
(86.4%) 
4 
(6.7%) 
4 
(6.7%) 
 
∗ In group I, 2cases (6.1%) had HTD and15cases (45.4%) had FGR in 
those cases with persistence of bilateral uterine artery notch. 
∗ In group I, 1 case (20.0%) had HTD and 3 cases (60.0%) had FGR in 
the case with persistence of unilateral uterine artery notch. 
∗ In group I, 4 cases (6.7%) had HTD, and 4 cases (6.7%) had FGR 
in the absence of notch. 
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 TABLE 
VIII- A 
GROUP – II 
 
Notch Number 
Normal 
outcome 
HTD FGR 
 
Bilateral 
12 
(12.2%) 
7 
(58.3%) 
1 
(8.3%) 
2 
(16.7%) 
 
Unilatera
 
6 
(6.1%) 
5 
(83.3%) 
0 
(0.0%) 
1 
(8.3%) 
 
Total 
18 
(18.4%) 
12 
(66.7%) 
1 
(5.5%) 
3 
(16.7%) 
 
Absent 
80 
(81.6%) 
79 
(98.7%) 
0 
(0.0%) 
0 
(0.0%) 
 
In group II, 1 case (8.3%) had HTD, 2 cases (16.7%) had FGR 
in the cases of persistence of bilateral uterine artery notch. 
 
In group II, no cases were reported to have hypertension in both 
unilateral and absent notches. 1 case (8.3 %) had FGR in the cases of 
persistence of unilateral uterine artery notch and no case had FGR in 
cases of absent notch. 
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 TABLE - VIII- B 
 
Notch Number FGR with 
HTD 
FGR without 
HTD 
HTD 
without 
 
Bilateral 12 
(12.2%) 
2 
(16.7%) 
3 
(25.0%) 
1 
(8.3%) 
Unilateral 6 
(6.1%) 
1 
(16.7%) 
1 
(16.7%) 
0 
(0.0%) 
Total 18 
(18.4%) 
3 
(16.7%) 
4 
(22.2%) 
1 
(5.5%) 
Absent 80 
(81.6%) 
0 
(0.0%) 
 
2 
(2.5%) 
2 
(2.5%) 
 
In  group  II,  2  cases  (16.7%)  had  HTD  with  FGR  in  cases  
with persistence of bilateral uterine artery notch. 
 
In group II, 1 case (16.7%) had HTD with FGR in the presence 
of unilateral uterine artery notch. 
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 Table - IX-A 
OVER ALL RESULTS:- 
 
Notch Number 
Normal 
outcome 
HTD FGR 
Bilateral 45 
(23.1%) 
23 
(51.1%) 
3 
(6.7%) 
17 
(37.8%) 
Unilateral 11 
(5.6%) 
6 
(54.5%) 
1 
(9.1%) 
4 
(36.4%) 
Total 56 
(28.7%) 
29 
(51.8%) 
4 
(7.1%) 
21 
(37.5%) 
Absent 139 
(71.3%) 
130 
(93.5%) 
4 
(2.9%) 
4 
(2.9%) 
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 Table - IX-B 
 
Notch Number 
FGR with 
HTD 
FGR 
without 
HTD 
HTD 
without 
FGR 
Bilateral 45 
(23.1%) 
18 
(40.0%) 
9 
(20.0%) 
3 
(6.7%) 
Unilateral 11 
(5.6%) 
4 
(36.4%) 
2 
(18.2%) 
1 
(9.1%) 
Total 56 
(28.7%) 
22 
(39.3%) 
11 
(19.6%) 
4 
(7.1%) 
Absent 139 
(71.3%) 
3 
(2.2%) 
 
3 
(2.2%) 
6 
(4.3%) 
 
In both groups (195 cases), notch was seen in 56 cases 
(28.7%). Among them 4 cases had HTD (7.1), 21 cases (37.5%) had 
FGR, 22 cases had FGR with HTD (39.3%). 
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 6. NOTCH AND HTD:-  
GROUP - I 
TABLE X-A 
NOTCH 
HTD 
Total 
Absent Present 
Absent 55 4 59 
Bilateral 31 2 33 
Unilateral 4 1 5 
Total 90 7 97 
 
P= 0.835 
Conclusion:  P-  value  of  0.835  indicates  insignificant  
relationship between notch and hypertensive disorder. 
 
0
10
20
30
40
50
60
Absent Bilateral Unilateral
55
31
44 2 1
Group I- Notch and HTD
Absent
Present
66 
 
 Table - X-B 
 
NOTCH 
HTD 
Total 
Absent Present 
Absent 78 2 80 
Bilateral 11 1 12 
Unilateral 6 0 6 
Total 95 3 98 
 
P= 0.923 
 
Conclusion:  P-value of 0.923 indicates insignificant relationship 
between notch and hypertensive disorder. 
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 7. NOTCH AND FGR:-  
GROUP - I 
TABLE XI-A 
 
NOTCH 
FGR 
Total 
Present Absent 
Absent 4 55 59 
Bilateral 15 18 33 
Unilateral 3 2 5 
Total 22 75 97 
 
P = <0.001 
 
Conclusion:  P- value of < 0.000 indicates significant relationship 
between notch and FGR. 
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 TABLE - XI-B 
GROUP II 
 
NOTCH 
FGR 
Total 
Present Absent 
Absent 2 78 80 
Bilateral 3 9 12 
Unilateral 0 6 6 
Total 5 93 98 
 
P = 0.092 
Conclusion:-  P - value of 0.092 indicates insignificant 
relationship between notch and FGR. 
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 8. NOTCH AND HTD-FGR:- 
TABLE - XII-A 
GROUP I 
 
NOTCH 
HTD-FGR 
Total Absent Present 
Absent 58 1 59 
Bilateral 27 6 33 
Unilateral 4 1 5 
Total 89 8 97 
 
P=0.022 
Conclusion: P value of 0.022 indicates significant relationship 
between notch and HTD-FGR. 
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 TABLE XIB 
 
NOTCH 
HTD-FGR 
 
Total Absent Present 
Absent 80 0 80 
Bilateral 10 2 12 
Unilateral 5 1 6 
Total 95 3 98 
 
P = 0.007 
Conclusion : P-value of 0.007 indicate significant relationship 
between bilateral notch and HTD- FGR. 
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 9. PERSISTENCE OF NOTCH AND HTD:- 
GROUP - I 
Table –XIII - A
 
Notch No of cases Gest HT 
Preeclampsia 
Mild Severe 
Bilateral 33 2 (6.1%) 6 (18.2%) 
10 
(30.3%) 
Unilateral 5 1 (20.0%) 1 (20.0%) 1 (20.0%) 
Total 38 3 (7.9%) 0 (0.0%) 0 (0.0%) 
Absent 
notch 
59 4 (6.8%) 0 (0.0%) 1(1.7%) 
 
In this study, in Group I i.e the cases with persistence of 
bilateral notch in 2 (6.1%) had gestational HT, 6 (18.2%) had mild 
preeclampsia and 10(30.3%) had severe preeclampsia. 
 
In the cases with persistence of unilateral notch 1(20.2%) had 
gestational HT, 1 (20.0%) had mild preeclampsia and 1 case (20.0%) had 
severe preeclampsia. 
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 Group - II 
Table – XIII - B 
 
Notch 
No of 
Cases 
Gest HT 
Preeclampsia 
Mild Severe 
Bilateral 12 1 (8.3%) 1 (8.3%) 1 (8.3%) 
Unilateral 6 0 1 (16.7%) 0 
Total 18 1 (5.5%) 2 (11.1%) 1 (5.5%) 
Absent 
notch 
80 2 (2.5%) 0 0 
 
In this study, in Group II i.e the cases of persistence of bilateral 
notch 1 (8.3%) had gestational HT, 1 (8.3%) had mild preeclampsia 
and 1(8.3%) had severe preeclampsia. 
 
In the cases of unilateral notch 1 case (16.7%) had mild 
preeclampsia.  
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 10. MODE OF DELIVERY AND PERSISTENCE OF NOTCH:- 
Group - I 
Table –XIV - A
 
Notch 
No of 
cases 
Mode of delivery 
Vaginal Caesarean 
Bilateral 33 
 
19 (57.6%) 14 (42.4%) 
Unilateral 5 3 (60.0%) 2 (40.0%) 
Total 38 22 (59.9%) 16 (42.1%) 
Absent 
 
59 49 (83.1%) 10 (16.9%) 
 
In Group I, in the presence of bilateral notch, 19 cases (57.6%) 
had vaginal delivery and 14 cases (42.4%) had caesarean delivery. 
 
In the presence of unilateral notch, 3 cases (60.0%) had 
vaginal delivery and 2 cases (40.0%) had caesarean delivery. 
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 Group II 
Table –XIV – B 
 
Notch No of cases 
Mode of delivery 
Vaginal Caesarean 
Bilateral 12 7 (58.3%) 5 (41.7%) 
Unilateral 6 5 (83.3%) 1 (16.7%) 
Total 18 12 (66.7%) 6 (33.3%) 
Absent notch 80 68 (85.0%) 12 (15.0%) 
 
In Group II, 7 cases (58.3%) had vaginal delivery and 5 cases 
(41.7%) had cesarean delivery in cases of bilateral notch, 5 cases(83.3%) 
had vaginal and 1 case (16.7%) had cesarean delivery with unilateral 
notch. 
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 11. PERSISTENCE OF NOTCH AND GESTATIONAL AGE AT 
DELIVERY:-
Group - I 
Table –XV – A 
 
Notch No of cases 
Gestational Age At Delivery 
<37 weeks >37 weeks 
Bilateral 33 10 (30.3%) 23 (69.7%) 
Unilateral 5 1 (20.0%) 4 (80.0%) 
Total 38 11 (28.9%) 27 (71.0%) 
Absent notch 59 5 (8.47%) 54 (91.5%) 
 
In Group I, in the presence of bilateral notch, 10 cases (30.3%) 
had delivery at less than 37 weeks of gestation and in the presence of 
unilateral notch, 1 case (20.0%) had delivery at less than 37 weeks of 
gestation. 
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 Group - II 
Table –XV – B 
 
 
Notch No of cases 
Gestational Age At Delivery 
<37 weeks >37 weeks 
Bilateral 12 2(16.7%) 10 (83.3%) 
Unilateral 6 2(33.3%) 4 (66.7%) 
Total 18 4 (22.2%) 14 (77.8%) 
Absent notch 80 0 (0%) 80 (100.0%) 
 
 
In Group II, in the presence of bilateral notch, 2 cases 
(16.7%) had delivery at less than 37 weeks of gestation and in the 
presence of unilateral notch 2 cases (33.3%) had delivery at less than 
37 weeks of gestation. 
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 12. PERSISTENCE OF NOTCH AND PERINATAL OUTCOME:- 
Group - I 
Table –XVI - A 
 
Notch 
Number of 
cases 
Perinatal outcome 
Abnormal Normal 
Bilateral 33 
17 
(51.5%) 
16 
(48.5%) 
Unilateral 5 
4 
(80.0%) 
1 
(20.0%) 
Total 38 
21 
(55.3%) 
17 
(44.7%) 
Absent notch 59 
8 
(13.6%) 
51 
(86.4%) 
 
In Group I, in the presence of bilateral notch, 17 cases (51.5%) 
had abnormal perinatal outcome and in the presence of unilateral 
notch 4 cases (80.0%) had abnormal perinatal outcome. 
 
Abnormal perinatal outcome was noted as apgar <6/10, 
meconium aspiration syndrome, respiratory distress, small for 
gestational age, preterm delivery and its complications and NICU 
admission. 
 
81 
 
 Group II 
Table –XVI - B
 
Notch Number of cases 
Perinatal outcome 
Abnormal Normal 
Bilateral 12 5 (41.7%) 7(58.3%) 
Unilateral 6 1(16.7%) 5(83.3%) 
Total 18 6 (33.3%) 12 (66.7%) 
Absent notch 80 1(1.2) 79(98.8%) 
 
 
In Group II, in the presence of bilateral notch, 5 cases (41.7%) 
had abnormal perinatal outcome and in the presence of unilateral 
notch 1case (16.7%) had abnormal perinatal outcome. 
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 13. NOTCH AND MODE OF DELIVERY:- 
 
Group I 
Table –XVII - A 
 
 
Notch 
Mode of delivery 
Total 
Caesarean Vaginal 
Absent 10 49 59 
Bilateral 14 19 33 
Unilateral 2 3 5 
Total 26 71 97 
 
 
P = 0.069 
 
Conclusion: P-value of 0.069 indicates insignificant relationship 
between notch and mode of delivery.  
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 Group II 
Table –XVII - B
 
NOTCH Mode of Delivery Total 
Caesarean Vaginal 
Absent 12 68 80 
Bilateral 5 7 12 
Unilateral 1 5 6 
Total 26 80 98 
 
P = 0.261 
 
Conclusion : P-value of 0.261 indicates  insignificant relationship 
between notch and mode of delivery. 
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 14. NOTCH AND GESTATIONAL AGE AT DELIVERY:- 
 
Group I 
Table –XVIII - A 
 
Notch 
Gestational age 
Total 
>37wks <37 wks 
Absent 54 4 58 
Bilateral 23 10 33 
Unilateral 4 1 5 
Total 81 15 96 
 
P = 0.482 
 
Conclusion : P-value of 0.482 indicates an insignificant 
relationship between notch and gestational age at delivery. 
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 Table XVIII-B 
Group II 
 
Notch 
Gestational age 
Total 
>37 wks <37 wks 
Absent 80 0 80 
Bilateral 10 2 12 
Unilateral 4 2 6 
Total 94 4 98 
 
P = 0.651 
Conclusion 
P-value of 0.651 (only at 5%) indicates an insignificant 
relationship between notch and gestational age at delivery.  
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 15. NOTCH AND PERINATAL OUTCOME:- 
Group I 
Table –XIX - A
 
Notch 
Perinatal outcome 
Total 
Abnormal Normal 
Absent 8 51 59 
Bilateral 17 16 33 
Unilateral 4 1 5 
Total 29 68 97 
 
P=0.003 
Conclusion : P-value of  0.003  (only at  5%)  indicates a 
significant relationship between notch and perinatal outcome. Abnormal 
Perinatal outcome is associated with Unilateral and Bilateral Notch. 
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 Group II 
Table –XIX - B 
 
Notch 
Perinatal Outcome 
Total 
Abnormal Normal 
Absent 1 79 80 
Bilateral 5 7 12 
Unilateral 1 5 6 
Total 7 91 98 
 
 
P=<0.001 
 
Conclusion : P-value of < 0.001 indicates significant ( at 5%) 
relationship notch and perinatal outcome. Notch is associated with 
perinatal abnormality. 
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 Doppler Study 
 
 Notch 
Out 
Come 
 + – 
+ TP a FN c 
– FP b TN d 
 
Following measures are used to evaluate a screening tests, 
 
1) Sensitivity  = 𝑎𝑎
𝑎𝑎 + 𝑐𝑐  × 100 
2) Specificity  = 𝑑𝑑
𝑏𝑏 + 𝑑𝑑  × 100 
3) Positive predictive value of the test = 𝑎𝑎
𝑎𝑎 + 𝑏𝑏  × 100 
4) Negative predictive value of the test = 𝑑𝑑
𝑐𝑐 + 𝑑𝑑  × 100 
5) Likelihood ratio (+) test = 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆1 –𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆 
6) Likelihood ratio (–) test = 1 − 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆
𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑆𝑆𝑆𝑆𝑆𝑆
 
7) Percentage of false positive = 𝑏𝑏
𝑏𝑏 + 𝑑𝑑  × 100 
8) Percentage of false negative = 𝑐𝑐
𝑎𝑎 + 𝑐𝑐  × 100 
  
 
92 
 
 Group - I 
1. Any Notch for HTD 
 
 Notch  
HTD 
 + –  
+ 3 4 7 
– 35 55 90 
  38 59 97 
 
 
1) Sensitivity  = 
37 × 100 = 42.85% 
2) Specificity  = 5590  × 100 = 61.11% 
3) Positive predictive value of the test = 
338  × 100 = 7.89% 
4) Negative predictive value of the test = 5559  × 100 = 93.22% 
5) Likelihood ratio (+) test = 
0.431 − 0.61 = 1.10% 
6) Likelihood ratio (–) test = 
1 − 0.430.60  = 0.93% 
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 2. Bilateral Notch for Hypertension  
 
 Bilateral Notch 
HTD 
 + –  
+ 2 4 6 
– 31 60 91 
 33 64 97 
 
1) Sensitivity  = 
26 × 100 = 33.3% 
2) Specificity  = 
6091  × 100 = 65.93% 
3) Positive predictive value of the test = 
233  × 100 = 6.1% 
4) Negative predictive value of the test = 
6064  × 100 = 93.75% 
5) Likelihood ratio (+) test = 
0.331 − 0.66 = 0.97 
6) Likelihood ratio (–) test = 
1 − 0.330.66  = 1.01 
 
 
 
 
 
94 
 
 3. Any Notch for FGR 
 Any Notch 
FGR 
 + –  
+ 18 4 22 
– 20 55 75 
 38 59 97 
 
 
1) Sensitivity  = 
1822  × 100 = 81.81% 
2) Specificity  = 5575  × 100 = 73.33% 
3) Positive predictive value of the test = 
1838  × 100 = 47.37% 
4) Negative predictive value of the test = 5559  × 100 = 93.22% 
5) Likelihood ratio (+) test = 
0.821 − 0.73 = 3.04 
6) Likelihood ratio (–) test = 
1 − 0.820.73  = 0.25 
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 4. Bilateral Notch for FGR 
 Bilateral Notch 
FGR 
 + –  
+ 15 4 19 
– 18 60 78 
 33 64 97 
 
 
1) Sensitivity  = 1519  × 100 = 78.95% 
2) Specificity  = 
6078  × 100 = 76.92% 
3) Positive predictive value of the test = 1533  × 100 = 45.45% 
4) Negative predictive value of the test = 
6064  × 100 = 93.74% 
5) Likelihood ratio (+) test = 
0.791 − 0.77 = 2.39 
6) Likelihood ratio (–) test = 
1 − 0.790.77  = 0.27 
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 Group II  
1. Any Notch for HTD 
 
 Any Notch 
HTD 
 + –  
+ 1 2 3 
– 17 78 95 
  18 80 98 
 
 
1) Sensitivity  = 
13 × 100 = 33.3% 
2) Specificity  = 
7895  × 100 = 82.10% 
3) Positive predictive value of the test = 
118  × 100 = 5.56% 
4) Negative predictive value of the test = 
7880  × 100 = 97.5% 
5) Likelihood ratio (+) test = 
0.331 − 0.91 = 3.66 
6) Likelihood ratio (–) test = 
1 − 0.330.91  = 0.73 
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 2. Bilateral Notch for Hypertension  
 
 Bilateral Notch 
HTD 
 + –  
+ 1 2 3 
– 11 84 95 
 12 86 98 
 
1) Sensitivity  = 
13 × 100 = 33.33% 
2) Specificity  = 
8494  × 100 = 88% 
3) Positive predictive value of the test = 
112  × 100 = 8.33% 
4) Negative predictive value of the test = 
8486  × 100 = 97.6% 
5) Likelihood ratio (+) test = 
0.331 − 0.88 = 2.75 
6) Likelihood ratio (–) test = 
1 − 0.330.88  = 0.76 
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 3. Any Notch for FGR 
 Any Notch 
FGR 
 + –  
+ 3 2 5 
– 15 78 93 
 18 80 98 
 
 
1) Sensitivity  = 
35 × 100 = 60% 
2) Specificity  = 
7893  × 100 = 83.8% 
3) Positive predictive value of the test = 
318  × 100 = 16.67% 
4) Negative predictive value of the test = 
7880  × 100 = 97.2% 
5) Likelihood ratio (+) test = 
0.601 − 0.83 = 3.52 
6) Likelihood ratio (–) test = 
1 − 0.600.83  = 1.5 
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 3. Bilateral Notch for FGR 
 Bilateral Notch 
FGR 
 + –  
+ 3 2 5 
– 9 84 93 
 12 86 98 
 
 
1) Sensitivity  = 
35 × 100 = 60% 
2) Specificity  = 
8493  × 100 = 90.32% 
3) Positive predictive value of the test = 
312  × 100 = 25% 
4) Negative predictive value of the test = 
8486  × 100 = 97% 
5) Likelihood ratio (+) test = 
0.61 − 0.9 = 6 
6) Likelihood ratio (–) test = 
1 − 0.60.9  = 0.4 
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 PREDICTION OF HTD /FGR BY UTERINE ARTERY DOPPLER 
SCREENING 
 
For Group - I 
 
 
Diagnostic 
Test 
Sensitivit
y Specificity PPV NPV 
LR for 
+ 
test 
(95
% 
CI) 
LR 
for (-
)Test 
(95% 
CI) 
FP FN 
For HTD 
Any 
notch 42.85% 61.11% 7.89% 93.22% 1.10 0.93 57.14% 92.10% 
Bilateral 
notch 33.33% 65.93% 6.1% 93.75% 0.97 1.01 66.67% 93.94% 
For FGR 
Any 
notch 81.81% 73.33% 47.37% 93.22% 3.04 0.25 18.18% 52.63% 
Bilateral 
notch 78.95% 76.92% 45.45% 93.75% 2.39 0.27 21.05% 54.55% 
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For Group – II 
Diagnostic 
Test Sensitivity Specificity PPV NPV 
LR 
for + 
test 
(95% 
CI) 
LR 
for (-) 
Test 
(95% 
CI) 
FP FN 
For HTD 
Any notch 33% 91% 5.5% 97.5% 3.66 0.73 17.8% 66.6% 
Bilateral 
notch 
33.3% 88% 8.3% 97.6% 2.74 0.76 11.57% 66.6% 
For FGR 
Any 
notch 
60% 83.8% 15% 97.5
% 
3.5 1.5 16.12% 40% 
Bilateral 
notch 
60% 90.32% 25% 97% 6 0.4 9.6% 40% 
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 DISCUSSION 
 
Doppler study application was made feasible first by Fitzgerald and 
Drumm. It is a noninvasive technique which uses high frequency sound 
waves for investigation of blood flow. 
 
 In group I,2 cases (6.1%) had HTD,15 cases (45.4%)  had FGR in  
cases with persistence  of  bilateral notch. 
 
 In Group I, 1 case (20.0%) had HTD, 3cases (60.0%) had FGR in 
the case with persistence of unilateral notch. 
 
 In Group I, 4 cases (6.7%) had HTD, and 4cases (6.7%) had FGR 
in case of absent notch. 
 
 In Group II, 1 case (8.3%) had HTD, 2cases (16.7%) had FGR in 
presence of bilateral   notch. 
 
 In Group II, no cases reported to have HT in both unilateral and 
absent notches. 
 
 1 case (8.3%) had FGR in case of persistence of unilateral notch 
and no case had FGR in case of absent notch. 
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  Bilateral notch persistence was associated with severe form of 
HTD and FGR compared to unilateral notch. 
 Rofinas et al(54) found persistence of diastolic notch in uterine 
artery with increased risk of HTD, FGR ,caesarean  delivery, 
preterm  delivery and admission to NICU. 
 Campbell et al (55)   first demonstrated relationship between HTD, 
FGR, fetal distress, increased cesarean delivery and low APGAR 
score with persistent bilateral diastolic notch. 
 Deutinger et al(56) found that early diastolic notch was associated 
with increased uteroplacental insuffiency. 
 Zimmermann et al (57) studied the utility of  uterine artery doppler  
between 21-24 weeks  in prediction  of  preeclampsia and FGR. 
Doppler was less informative in cases of low risk. In case of 
bilateral notch, there is increased risk of preeclampsia and FGR. In 
case of bilateral notch, preeclampsia and FGR was noted in 58.3% 
compared to 8.3% in absent notch. 
 Pai(58) found  that  in predicting  HTD/FGR ,persistent diastolic 
notch  was a better parameter than Resistant  index. 
 Flesicher et al conducted the study after 26 weeks and found that 
early diastolic notch was associated with increased cesarean 
rate,preeclampsia,FGR,fetal distress and admission  to NICU. 
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  Thaler et al (59) found diastolic notch as a better outcome than S/D 
ratio and Resistance index (RI). 
 Bower et al also found correlation between diastolic notch and 
HTD,FGR,fetal distress. 
 Trudinger et al (60) studied only high risk patients for prediction of 
preeclampsia, FGR. 
 In this study, in Group I, in case of bilateral notch ,6.1% had 
gestational HT,18.2% had  mild  preeclampsia,30.3% had  severe 
preeclampsia. 
 In case of unilateral notch, 20.0% had gestational HT, 20.0% had 
mild preeclampsia, 20.0% had severe preeclampsia. 
 In Group II, in cases of persistence of bilateral notch 8.3% had 
gestational HT, 8.3% had mild preeclampsia, 8.3% had severe 
preeclampsia. 
 In case of unilateral notch 16.7% had mild preeclampsia. 
 In Group I, in presence of bilateral notch 42.4% had cesarean 
delivery, in case of unilateral notch 40.0% had cesarean delivery. 
 In Group II, in presence of bilateral notch 41.7% had cesarean 
delivery compared to 16.7% in case of unilateral notch. 
 Overall, increased risk of cesarean delivery is noted in Group I 
(High risk) cases and that to in cases with persistent bilateral  
notches. 
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  Aristidou et al (61) and Christopher Lees(62) demonstrated  persistent 
diastolic notches with increased risk of  HT,FGR  and low APGAR 
scores. 
 In this study, preterm delivery was more common in High risk 
(Group I) cases. 
 In Group I, 30.3% had preterm delivery in case of bilateral 
notches,and only 20.0% had preterm delivery in case of unilateral 
notches. 
 The useful part of a test depends on negative predictive 
value.Negative predictive value of 100% in Group II (low risk) 
indicates that both HT/FGR will not be present. 
 
Validity of tests in Group I&II for any notch and bilateral notch 
for hypertensive disorder/ fetal growth restriction when compared to 
other studies were, 
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 For prediction of PIH 
 
Author Sensitivity Specificity 
Positive 
predictive 
value 
Negative 
predictive 
value 
Agarwal 84 71.4 72 - 
Papageorghiou et 
 
41% - - - 
Bower et al 78 96 28 99.5 
May Backos et al 38 85 27 90 
Campbell et al 68% 69% - - 
Pai 45.45 92 38 93.87 
 
 
In this study, Group I 
 
Diagnosti
c 
Test 
Sensitivi
ty 
Specificit
y PPV NPV 
LR for 
+ 
test 
(95
% 
CI) 
LR 
for (-) 
Test 
(95% CI) 
FP FN 
For HTD 
Any notch 42.85% 61.11% 7.89% 93.22% 1.10 0.93 57.14% 92.10% 
Bilateral 
notch 
33.33% 65.93% 6.1% 93.75% 0.97 1.01 66.67% 93.94% 
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 Group II 
 
Diagnostic 
Test 
Sensitiv
ity Specificity PPV NPV 
LR 
for + 
test 
(95% 
CI) 
LR 
for (-) 
Test 
(95% 
CI) 
FP FN 
For HTD 
Any notch 33% 91% 5.5% 97.5% 3.66 0.73 17.8% 66.6% 
Bilateral 
notch 
33.3
% 
88% 8.3% 97.6% 2.74 0.76 11.57% 66.6% 
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For prediction of FGR 
 
Author Sensitivity Specificity 
Positive 
predictive 
value 
Negative 
predictive 
value 
May Backos et al 41% 85% 30% 90% 
Papageorghiou et al 24% - - - 
 
 
In this study, Group I 
 
 
Diagnostic 
Test 
Sensitivit
y Specificity PPV NPV 
LR for 
+ test 
(95% 
CI) 
LR 
for 
(-) 
Test 
(95% 
CI) 
FP FN 
For FGR 
Any notch 
81.81% 73.33% 47.37% 93.22% 3.04 0.25 18.18% 52.63% 
Bilateral 
notch 
78.95% 76.92% 45.45% 93.75% 2.39 0.27 21.05% 54.55% 
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In this study, Group II 
 
Diagnostic 
Test 
Sensitivit
y Specificity PPV NPV 
LR 
for + 
test 
(95
% 
CI) 
LR 
for (-) 
Test (95% 
CI) 
FP FN 
For FGR 
Any notch 60% 83.8% 15% 97.5% 3.5 1.5 16.12% 40% 
Bilateral 
notch 
60% 90.32% 25% 97% 6 0.4 9.6% 40% 
 
 
Ashraf Jamal 
et al 
Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Preeclampsia 30.4 90.5 15.2 95.9 
FGR 47.1 90.9 17.4 97.7 
 
 
Author 
Sensitivity 
Preeclampsia FGR 
Albaiges et al 35% 21% 
Harrington et al 55% 22% 
Bowley et al 1991 - 10% 
Steel et al 1990 - 33% 
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Prajapati 
Saloni. R. 
Nandita et al 
Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
LR + 
Test 
LR - 
Test 
Preeclampsia 30 94 50 87.22 5.06 0.74 
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 SUMMARY 
IN GROUP-I (HIGH RISK) 
 71% of cases belonged to 21-30 yrs,12% of cases belonged  to 18-
20 yrs,17% belonged  to  31-35 yrs. 
 All the 100 cases were multigravida. 
 Bilateral notch was present in 34.02% of cases, Unilateral notch 
was present in 5.15% of cases. 
 6.1%  had HTD, 45.4%  had FGR,18.2% had  HTD with 
FGR,42.4%  had casarean delivery,30.3%  had preterm delivery 
and 51.5% had  abnormal  perinatal  outcome in  cases of  
persistent diastolic notch. 
 20.0% had HTD,60.0% had FGR,1.7% had  HT with FGR,40% 
had  cesarean delivery,20.0% had preterm  delivery and 80.0% had  
abnormal outcome in case  of unilateral notch. 
 6.7% had HTD, 6.7% had FGR, 1.7% had both HT and FGR, 
16.9% had cesarean delivery, 8.47% had preterm delivery and 
13.6% had abnormal outcome with absent notches. 
  In Group I, there is a significant association between notch and 
parity, FGR, both HT/FGR, abnormal perinatal outcome, and 
insignificant association between notch and HT, mode of delivery, 
gestational at delivery. In the presence of notch there is increased 
risk of FGR, both HT/FGR and abnormal perinatal outcome. 
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 FOR GROUP I 
 
Diagnosti
c 
Test 
Sensitivi
ty 
Specifici
ty PPV NPV 
LR for 
+ test 
(95% 
CI) 
LR 
for (-
)Test 
(95% 
CI) 
FP FN 
For HTD 
Any notch 42.85% 61.11% 7.89% 93.22% 1.10 0.93 57.14% 92.10% 
Bilateral 
notch 
33.33% 65.93% 6.1% 93.75% 0.97 1.01 66.67% 93.94% 
For FGR 
Any 
notch 
81.81% 73.33% 47.37% 93.22% 3.04 0.25 18.18% 52.63% 
Bilateral 
notch 
78.95% 76.92% 45.45% 93.75% 2.39 0.27 21.05% 54.55% 
 
FOR GROUP II 
Diagnostic 
Test 
Sensiti
vity 
Specificit
y PPV NPV 
LR 
for + 
test 
(95% 
CI) 
LR 
for (-
)Test 
95% 
CI) 
FP FN 
For HTD 
Any notch 33% 91% 5.5% 97.5% 3.66 0.73 17.8% 66.6% 
Bilateral 
notch 
33.3
% 
88% 8.3% 97.6% 2.74 0.76 11.57
% 
66.6% 
For FGR 
Any notch 60% 83.8% 15% 97.5
 
3.5 1.5 16.12
 
40% 
Bilateral 
notch 
60% 90.32% 25% 97% 6 0.4 9.6% 40% 
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 IN GROUPII (LOW RISK) 
 72% of cases belonged to 21-30 yrs,25% belonged to 18-20 yrs,3% 
of cases belonged to 31-35 yrs of age. 
 40% cases were multigravida, 60% of cases were primigravida. 
 Bilateral notch was present in 12.24% of cases, 6.12% of cases had 
unilateral notch. 
 8.3% had HTD, 16.7% had FGR,16.7% had both HT/FGR,41.7% 
had cesaerean delivery,16.7% had preterm delivery,41.7% had 
abnormal perinatal outcome in cases with bilateral diastolic 
notches. 
 8.3% had FGR, 16.7% had both FGR and HT,16.7% had cesaerean 
delivery,33.3% had preterm  delivery and 16.7%  had abnormal 
perinatal outcome in cases with unilateral  outcome. 
 1.2 % had abnormal out come with absent notch. 
 In this study in Group II,there is significant  association between 
notch and parity,both FGR and HT,perinatal outcome.Insignificant  
association between notch  and HT,FGR,mode of  delivery,and 
gestational  age at delivery. 
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 CONCLUSION 
 
 Prevention is better than cure; though preeclampsia is not a 
preventable disease; early prediction helps in increased fetal 
surveillance and timely interventions. 
 From  the study it is concluded  that in Group I (High risk ),in case 
of  bilateral notches   there is increased risk of  preeclampsia, FGR, 
preterm delivery and abnormal perinatal outcome compared to 
cases with unilateral  notches and absent notches. 
 In Group II (low risk) cases also, bilateral notches are associated 
with increased risk of preeclampsia, FGR, Preterm delivery and 
abnormal perinatal outcome compared to unilateral and absent 
notches. 
 In both Group I and Group II, bilateral diastolic notch was 
associated with poor prognosis. 
 It  is better to do Uterine artery doppler study ,along  with  Target 
scan at 20-22 weeks of  gestation, thereby both anomalies of fetus 
and risk of preeclampsia ,FGR  can be predicted in the same visit. 
 Prediction  value  of  Uterine artery doppler study  is increased by 
doing  the  test along  with  serum beta HCG, PAPPA, inhibin A. 
 Cost of the test is the drawback in doing the test in government 
setup. 
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  From the study, it is concluded that in Group I and II, those cases 
with bilateral notch require more fetal surveillance and timely 
intervention compared to unilateral and absent notch. 
 Cases with absent notches require only routine checkup and not 
frequent checkup. 
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 PROFORMA 
Name  :                       
Age  :               
IP No  :               
Unit  : 
Address :                                       
 
Parity  :                 
Occupation : 
LMP   : 
EDD   : 
Any specific complaints  : 
 
Menstrual History  : 
Marital History   : 
Obstetric History  : 
Personal / past History  : 
Family History    : 
General Examination  :                          
Height  :   Weight : 
Vital signs :  
PR :   BP :    CVS :  RS : 
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 Obstetric examination : 
Investigations  : 
1. Urine Analysis  :                   
2. Blood   : 
3. USG Obstetrics  : 
4. Doppler - Uterine Artery  : 
     Presence of Notch - Unilateral : 
                                    - Bilateral    
     Absence of  notch : 
5. Development of HTD/FGR : 
6. Mode of delivery : 
               Vaginal  : 
               Caesarean : 
7. Gestational age at delivery : 
8. Perinatal outcome : 
    Birth weight  : 
    APGAR   : 
     NICU Admission : 
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Unilateral Bilateral absent
1 vijaya M 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
2 mallika M 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
3 mari M 21 0 B 0 0 0 0 0 FGR 0 V 0 0 T NPO 0
4 ranjana M 22 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
5 chitra M 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
6 vasaki M 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
7 karupayee M 23 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
8 buvana M 17 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
9 rajalakshmi M 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
10 sudha M 24 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
11 veeralakshmi M 23 0 0 A N 0 0 0 0 0 0 L 0 T 0 APO
12 sundarammal M 25 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
13 durgadevi M 24 0 0 A N 0 0 0 0 0 0 L 0 T 0 APO
14 shanthi M 26 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
15 soniya M 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
16 bharathi M 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
17 malar M 27 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
18 pandeswari M 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
19 mathi M 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
20 sujatha M 28 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
21 valliyamml M 29 0 B 0 0 0 MP 0 0 0 0 L 0 T NPO 0
22 priyanka M 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
23 kavya M 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
24 kumari M 29 0 B 0 0 0 MP 0 0 0 V 0 0 T NPO 0
25 petchiammal M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
26 malliga M 26 0 B 0 0 GHT 0 0 0 0 0 L 0 T NPO 0
27 malar M 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
28 rajeshwri M 26 0 0 A N 0 0 SP FGR BOTH V 0 0 T NPO 0
29 ramya M 25 0 B 0 0 0 0 SP 0 0 0 L P 0 0 APO
30 anbarasi M 24 0 B 0 0 0 0 SP 0 0 0 L P 0 0 APO
31 anu M 23 0 B 0 0 0 0 SP 0 0 0 L P 0 0 APO
32 augusta M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
33 beula M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
34 kalaiselvi M 21 0 B 0 0 0 0 SP FGR 0 0 L P 0 0 APO
35 sumathy M 30 0 B 0 0 0 0 SP FGR 0 0 L P 0 0 APO
36 ramalkshmi M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
37 sankari M 33 0 B 0 0 0 0 SP FGR BOTH 0 L P 0 0 APO
38 amutha M 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
39 pattulakshmi M 33 0 B 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
Notch
S.No. Name Parity Age
Abnormal 
Perinatal 
Outcome
Normal (No 
Hypertension, 
Fgr)
Gestational 
Hypertensio
n 
Mild 
preeclam
psia
Severe 
preeclam
psia
FGR HT and FGR
Vaginal 
delivery LSCS
Preterm 
delivery
Term 
delivery
Normal 
Perinatal 
Outcome
40 aruna M 32 0 B 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
41 banu M 31 0 B 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
42 eskkiammal M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
43 mohammed nisha M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
44 viji M 32 0 B 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
45 kamalam M 33 0 B 0 0 0 0 0 FGR 0 V 0 0 T NPO 0
46 nageeshwari M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
47 selvi M 34 U 0 0 0 0 0 SP FGR BOTH V L 0 T NPO 0
48 valli M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
49 patta M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
50 sorna M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
51 latha M 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
52 divya M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
53 rathi M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
54 varalakshmi M 21 0 0 A 0 0 0 0 FGR 0 0 0 0 T 0 APO
55 kavitha M 33 U 0 0 0 0 0 0 FGR 0 0 0 0 T 0 APO
56 aathilakshmi M 22 0 0 A N 0 0 0 0 0 0 L 0 T 0 APO
57 murugammal M 25 0 0 A 0 GHT 0 0 0 0 0 L P T 0 APO
58 lakshmi M 26 0 0 A 0 GHT 0 0 0 0 0 L P 0 0 APO
59 kavitha M 28 0 0 A 0 GHT 0 0 0 0 0 L P 0 NPO 0
60 kaliammal M 27 0 0 A 0 GHT 0 0 0 0 0 L P 0 0 APO
61 knagalakshmi M 29 0 0 A 0 0 0 0 FGR 0 0 L P 0 0 APO
62 radha M 30 0 0 A 0 0 0 0 FGR 0 0 L P 0 NPO 0
63 mookayee M 27 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
64 pappa M 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
65 madathi M 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
66 vinotha M 30 0 B 0 0 0 MP 0 0 0 0 L 0 T NPO 0
67 raji M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
68 rani M 35 0 B 0 0 0 MP 0 FGR BOTH V 0 0 0 0 APO
69 meena M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
70 priyanka M 25 0 0 A 0 0 0 0 0 0 V 0 0 T NPO 0
71 sardha M 28 0 B 0 0 0 MP 0 0 0 V 0 0 T NPO 0
72 mookaye M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
73 moupidathi M 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
74 annalakshmi M 27 0 B 0 0 GHT 0 0 0 0 0 L 0 T NPO 0
75 murugammal M 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
76 vanishree M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
77 kumari M 22 0 B 0 0 0 0 SP 0 0 0 L P 0 0 APO
78 sundari M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
79 subashini M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
80 thilaga M 31 0 B 0 0 0 0 SP FGR BOTH 0 L P 0 0 APO
81 mariammal M 21 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
82 annlkshmi M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
83 krithiga M 32 0 B 0 0 0 0 SP FGR BOTH 0 L P 0 0 APO
84 sabeena M 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
85 sudali M 34 0 B 0 0 0 0 SP FGR BOTH 0 L P 0 0 APO
86 valar M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
87 parvathy M 34 0 B 0 0 0 MP 0 FGR BOTH V 0 0 T 0 APO
88 santhanmri M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
89 geethalakshmi M 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
90 sumitha M 31 0 B 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
91 indira M 33 U 0 0 0 0 MP 0 0 0 V L 0 T 0 APO
92 kumari M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
93 booma M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
94 gomathy M 35 U 0 0 0 GHT 0 0 0 0 0 0 P T 0 APO
95 chitra M 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
96 umrani M 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
97 esakkiammal M 35 U 0 0 0 0 0 0 FGR 0 V 0 0 T 0 APO
98 ramu M 24
99 sudha M 23
100 pandaram M 26
M- Multigravida
U- Unilateral
B-Bilateral
A-absent+A1
N-Normal (No Hypertension, Fgr)
G-Gestational Hypertension 
MP-Mild preeclampsia
SP-Severe preeclampsia
FGR-Fetal Growth Restriction
BOTH- FGR and Hypertension
V-Vaginal delivery
L-LSCS
P-Preterm delivery
T-Term delivery
NPO-Normal Perinatal Outcome
APO-Abnormal Perinatal Outcome
Unilateral Bilateral Absent
1 krishnaveni PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
2 vanitha PR 18 U 0 0 N 0 0 0 0 0 V 0 P 0 NPO 0
3 rajam M 32 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
4 madhu M 33 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
5 palaniammal PR 18 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
6 manjula M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
7 petchiammal PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
8 mary M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
9 snthanam M 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
10 vani PR 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
11 vasanthi M 21 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
12 boothapandichi PR 17 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
13 vellathai PR 16 U 0 0 N 0 0 0 0 0 V 0 0 T NPO 0
14 sornam M 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
15 ponezaki M 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
16 usha PR 17 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
17 valliamml PR 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
18 lakshmi M 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
19 pandiammal PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
20 amutha PR 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
21 sundari M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
22 kousalya PR 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
23 sudali PR 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
24 kannagi PR 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
25 ranjitham M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
26 kodi PR 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
27 ganga PR 20 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
28 venmathi M 25 0 B 0 0 0 0 SP FGR 1 0 L 0 T NPO 0
29 viji M 24 0 B 0 0 0 MP 0 FGR 1 0 L 0 T NPO 0
30 meena PR 22 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
31 sathya M 22 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
32 subha M 21 0 0 A N 0 0 0 FGR 0 0 L 0 T NPO 0
33 nagalakshmi PR 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
34 indumathy M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
35 vani M 34 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
36 revathi PR 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
37 packiam PR 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
38 shanthi PR 27 0 B 0 N 0 0 0 0 0 0 L P 0 0 APO
39 vidya M 26 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
40 shanmugasundari PR 26 0 0 A N 0 0 0 0 0 V 0 0 NPO 0
41 nabeesha PR 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
42 arumagaselvi PR 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
43 ramya PR 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
44 lalitha M 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
45 ramalakshmi PR 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
46 tamil selvi PR 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
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47 eskiammal PR 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
48 sngeetha PR 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
49 pandiammal PR 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
50 amalapushpam M 21 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
51 peratchi PR 20 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
52 poongodi PR 17 U 0 0 N 0 0 0 0 0 V 0 P 0 0 APO
53 guruvammal M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
54 avudaiammal PR 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
55 mariammal PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
56 andal selvi M 22 0 0 A N 0 0 0 0 0 V 0 0 T 0 APO
57 muthumari M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
58 anitha PR 17 U 0 0 N 0 0 0 0 0 V 0 0 T NPO 0
59 malliga M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
60 kamala M 23 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
61 usha PR 18 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
62 mary PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
63 rani M 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
64 kavitha PR 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
65 aandal selvi PR 27 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
66 natchiyar PR 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
67 arumugam M 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
68 jyothi M 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
69 kothai PR 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
70 manimegalai PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
71 thangam M 22 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
72 murugammal PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
73 sankarammal M 27 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
74 surya PR 18 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
75 ragi PR 19 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
76 amali M 26 0 B 0 N 0 0 0 0 0 V 0 0 T NPO 0
77 shakthi PR 28 0 B 0 N 0 0 0 0 0 0 L P 0 NPO 0
78 gomathi PR 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
79 seeniammal M 23 0 0 A 1 0 0 0 0 0 0 L 0 T NPO 0
80 malathi PR 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
81 jeyalakshmi PR 24 0 B 0 N 0 0 0 0 0 V 0 0 T 0 APO
82 mookammal PR 21 0 B 0 0 0 0 0 1 0 0 L 0 T NPO 0
83 ponnuthai M 30 0 0 A N 0 0 0 FGR 0 0 L 0 T NPO 0
84 mageshwari PR 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
85 balammal PR 22 0 B 0 0 G 0 0 0 0 V 0 0 T 0 APO
86 vimala PR 30 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
87 padmavathy M 29 0 0 A N G 0 0 0 0 0 L 0 T NPO 0
88 thulasi M 23 0 0 A N G 0 0 0 0 0 L 0 T NPO 0
89 rajeshwari PR 24 0 B 0 N 0 0 0 0 0 V 0 0 T 0 APO
90 subbulakshmi PR 26 0 B 0 N 0 0 0 0 0 V 0 0 T 0 APO
91 jeyachitra M 25 0 0 A N 0 0 0 0 0 0 L 0 T NPO 0
92 ambal M 27 U 0 0 N 0 0 0 0 0 V 0 0 T NPO 0
93 fathima PR 24 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
94 rajalakshmi PR 26 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
95 diana M 29 U 0 0 0 0 MP 0 FGR BOTH 0 L 0 T NPO 0
96 nallathai PR 28 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
97 veni M 30 - - - - - - - - - - - - - - -
98 selvi PR 25 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
99 antonyammal PR 29 0 0 A N 0 0 0 0 0 V 0 0 T NPO 0
100 velammal M 28 - - - - - - - - - - - - - - -
PR-Primi
M-Multigravida
U-Unilateral
B-Bilateral
A-Absent
N-Normal (No Hypertension, Fgr)
G-gestational Hypertension 
MP-mild preeclampsia
SP-severe preeclampsia
FGR-Fetal Growth Restriction
BOTH- FGR and Hypertension
V-Vaginal delivery
L-LSCS
P-Preterm delivery
T-Term delivery
NPO-Normal Perinatal Outcome
APO-Abnormal Perinatal Outcome
